Prime Medicine, Inc. (PRME) Current Ratio
- Current ratio · latest quarter: Value 3.05×; Formula and calculation Current assets / current liabilities..
Current ratio
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Current ratio · latest quarter | 3.05× | Current assets / current liabilities. $96.80M ÷ $31.69M ≈ 3.05× |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Current assets | 96.80M USD | Assets, Current |
| Current obligations | 31.69M USD | Liabilities, Current |
| Cash and equivalents | 47.45M USD | Cash and Cash Equivalents, at Carrying Value |
| Short-term securities | 47.62M USD | Debt Securities, Available-for-sale, Current |
| Customer receivables | (m) | |
| Inventory | (m) | |
| Payables | 5.81M USD | Accounts Payable, Current |
| Borrowing debt due within one year | (m) |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Current assets (USD) | Current obligations (USD) | Cash and equivalents (USD) | Short-term securities (USD) | Customer receivables (USD) | Inventory (USD) | Payables (USD) | Borrowing debt due within one year (USD) | Current ratio |
|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $96.80M | $31.69M | $47.45M | $47.62M | (m) | (m) | $5.81M | (m) | 3.05× |
| 2026-03-31 | $137.89M | $36.29M | $64.11M | $71.39M | (m) | (m) | $12.32M | (m) | 3.80× |
| 2025-12-31 | $181.29M | $37.45M | $63.03M | $114.65M | (m) | (m) | $8.89M | (m) | 4.84× |
| 2025-09-30 | $231.41M | $35.02M | $71.40M | (m) | (m) | (m) | $9.35M | (m) | 6.61× |
| 2025-06-30 | $121.29M | $34.11M | $53.80M | (m) | (m) | (m) | $6.38M | (m) | 3.56× |
| 2025-03-31 | $163.76M | $34.29M | $91.88M | (m) | (m) | (m) | $10.03M | (m) | 4.78× |
| 2024-12-31 | $211.89M | $37.96M | $182.48M | (m) | (m) | (m) | $11.35M | (m) | 5.58× |
| 2024-09-30 | $246.07M | $37.88M | $117.98M | (m) | (m) | (m) | $5.43M | (m) | 6.50× |
| 2024-06-30 | $170.80M | $20.75M | $55.60M | (m) | (m) | (m) | $4.64M | (m) | 8.23× |
| 2024-03-31 | $217.65M | $24.44M | $94.16M | (m) | (m) | (m) | $10.08M | (m) | 8.91× |
| 2023-12-31 | $142.98M | $56.42M | $41.57M | (m) | (m) | (m) | $19.54M | (m) | 2.53× |
| 2023-09-30 | $184.53M | $39.37M | $43.96M | (m) | (m) | (m) | $14.12M | (m) | 4.69× |
| 2023-06-30 | $218.49M | $28.72M | $120.58M | (m) | (m) | (m) | $5.49M | (m) | 7.61× |
| 2023-03-31 | $253.50M | $23.87M | $133.46M | $109.92M | (m) | (m) | $4.56M | (m) | 10.62× |
| 2022-12-31 | $296.62M | $26.71M | $187.62M | (m) | (m) | (m) | $4.33M | (m) | 11.10× |
| 2022-09-30 | $148.84M | $22.22M | $47.95M | $89.17M | (m) | (m) | $4.11M | (m) | 6.70× |
| 2021-12-31 | $270.58M | $57.98M | $185.42M | $68.24M | (m) | (m) | $1.44M | (m) | 4.67× |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Allogene Therapeutics, Inc. (ALLO) | United States | $0.574B | -4.33 |
| Autolus Therapeutics plc (AUTL) | $0.506B | -1.52 | |
| Entera Bio Ltd. (ENTX) | $0.485B | ||
| REGENXBIO Inc. (RGNX) | United States | $0.477B | -3.30 |
| Aura Biosciences, Inc. (AURA) | United States | $0.639B | -5.61 |
| Tectonic Therapeutic, Inc. (TECX) | United States | $0.469B | -7.68 |
| Eikon Therapeutics, Inc. (EIKN) | United States | $0.446B | |
| Kyverna Therapeutics, Inc. (KYTX) | United States | $0.434B | -3.60 |
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B |